MedTrace Logo

The Effect of Exparel on Post Operative Pain and Narcotic Use After Colon Surgery

NCT02052557 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2021-01-08

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to evaluate the effect of Exparel on pain control and patient outcome after colon resection. The investigators will evaluate the clinical course of the patients who receive exparel as compared to the patients who do not receive exparel. Exparel is a 72 hour bupivacaine which is slowly released from lysosomes over the course of three days. A long acting local anesthetic should provide better pain control than conventional bupivacaine which has a 3.5 hour half-life.

Conditions

Interventions

DRUG

Bupivacaine

30ml of bupivacaine were injecting into the subcutaneous tissue at the incision sites after surgery in the OR

DRUG

Bupivacaine liposome suspension

30ml of Bupivacaine liposome injectable suspension were injecting into the subcutaneous tissue at the incision sites after surgery in the OR

Sponsors & Collaborators

  • Mercy Medical Center

    collaborator OTHER

  • Des Moines University

    lead OTHER

Principal Investigators

  • Rachel Knudson, DO · Mercy Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02052557 on ClinicalTrials.gov